SRC
REGN icon

Shufro Rose & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

Shufro Rose & Co’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Hold
0
– -$285K – 318
2024
Q4 		– Hold
0
– – – 233
2022
Q1 		– Sell
-500
Closed -$316K – 357
2021
Q4 		$316K Buy
+500
New +$307K 0.02% 220

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Shufro Rose & Co's REGN Position: Q1 2026 in Review

Shufro Rose & Co reduced its Regeneron Pharmaceuticals (REGN) stake by 1.4% in Q1 2026, selling an estimated $28.3K and leaving 2,598 shares worth $2.01M. The position accounts for 0.14% of the portfolio, ranked #80.

Shufro Rose & Co first reported a position in REGN in Q1 2016 and has held it in 35 quarters since. The position peaked at $2.03M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Shufro Rose & Co held 2,598 shares of Regeneron Pharmaceuticals worth $2.01M as of Q1 2026.
  • Shufro Rose & Co sold 37 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $28.3K.
  • Regeneron Pharmaceuticals made up 0.14% of Shufro Rose & Co's portfolio in Q1 2026, its #80 holding.
  • Shufro Rose & Co first reported a position in Regeneron Pharmaceuticals in Q1 2016 and has held it in 35 quarters since.
  • Shufro Rose & Co's Regeneron Pharmaceuticals position peaked at $2.03M in Q4 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Shufro Rose & Co's 13F filing for Q1 2026, filed 15 May 2026.